AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role
Injection Cut Risk By 50%
Executive Summary
AstraZeneca’s anti-SARS-CoV-2 antibody product is unlikely to rival Regeneron or Vir/GSK’s offerings in mild-to-moderate patients, where Merck’s newly-submitted oral molnupiravir will also change treatment.
You may also be interested in...
Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
AstraZeneca COVID-19 Antibody Could Be Solution For Vulnerable But Not Vaccine Alternative
AZD7442 can provide antibodies in people who cannot generate their own after vaccination but could in theory also be used to protect other groups, including unvaccinated populations.
Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.